ストックスクリーナーアプリを入手
111.67
0.04%
-0.04
アフターアワーズ：
111.67
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance
Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Canada
LGND: 3Q Sales Surprise to the Upside - Zacks Small Cap Research
Lisanti Capital Growth LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 7.7%Should You Sell? - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript - Insider Monkey
Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Villere ST Denis J & Co. LLC Lowers Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast - Investing.com India
Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $150.00 at Barclays - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Given Buy Rating at HC Wainwright - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highligh - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Ligand: Q3 Earnings Snapshot - Houston Chronicle
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance - BioSpace
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY24 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $116.25 - Investing.com
Ligand Pharmaceuticals stock hits 52-week high at $116.25 By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from HC Wainwright - Defense World
Macquarie Group Ltd's Strategic Reduction in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals (STU:LGDN) Preferred Stock : €0.0 Mil (As of Jun. 2024) - GuruFocus.com
Ligand Pharmaceuticals (FRA:LGDN) Momentum Rank : 6 (As of Nov. 01, 2024) - GuruFocus.com
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston - StockTitan
Stephens Investment Management Group LLC Sells 33,304 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings - Simply Wall St
Congress Asset Management Co. Has $60.46 Million Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC Wainwright - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $125.00 - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Raised by Allspring Global Investments Holdings LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighTime to Buy? - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $112.25 - Investing.com
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 - Marketscreener.com
Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00 at HC Wainwright - Defense World
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00 - MarketBeat
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts - Benzinga
Chicago Capital LLC Has $54.63 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Yahoo Finance
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):